Burning Rock Biotech vs Concord Medical Services
BNR and CCM side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BNR and CCM compare
Concord Medical Services grew revenue faster over the last twelve months (19.9% versus 4.6% for Burning Rock Biotech).
Burning Rock Biotech keeps more of each dollar of sales as profit, with a net margin of −10.3% compared with −20.2% at Concord Medical Services.
Burning Rock Biotech scores higher on the StockData Score (4 against 3 for Concord Medical Services), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BNR | CCM |
|---|---|---|
| Size and price | ||
| Share price | $12.74 | $3.59 |
| Change, 1 year | 12.5% | −22.0% |
| Change, 5 years | −90.8% | −84.8% |
| Beta (5Y) | 2.50 | 1.18 |
| Employees | 667 | 610 |
| StockData Score | ||
| Total score | 4 (better) | 3 |
| Valuation score | 0 | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 1 | 1 |
| Health score | 2 (better) | 0 |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | 4.6% | 19.9% (better) |
| Revenue growth, 5Y average | 4.6% | 15.6% (better) |
| Profitability | ||
| Gross margin | 74.7% (better) | 5.6% |
| Operating margin | −10.2% (better) | −56.8% |
| Net margin | −10.3% (better) | −20.2% |
| FCF margin | −6.2% (better) | −56.1% |
| Return on equity | −9.9% | – |
| Return on invested capital | −72.5% | −19.3% (better) |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −1.7× |
| Current ratio | 2.99 (better) | 0.48 |
| Piotroski F-score | 5 | 6 (better) |
| Ownership | ||
| Held by institutions | 1.8% | 0.03% |
| Held by insiders | 19.0% | 0.83% |
| Insider net buying, 12 months | $11.6M | – |
Go deeper
- BNR stock overview
- BNR income statement
- BNR valuation and score
- CCM stock overview
- CCM income statement
- CCM valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.